(Q36723814)

15 August 2017

1 reference

title

Immunomodulatory therapy in yeast infections (English)

1 reference

15 August 2017

3

Emmanuel Roilides

1 reference

15 August 2017

Jorge Garbino

1

1 reference

15 August 2017

Aspasia Katragkou

series ordinal

2

1 reference

15 August 2017

publication date

1 February 2007

1 reference

Expert Review of Anti-infective Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

5

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

129-140

1 reference

Changing patterns and trends in systemic fungal infections

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Invasive candidiasis in immunocompromised hospitalized patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Changing spectrum of invasive candidiasis and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Immunity to fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Immunomodulation of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, an

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Recombinant cytokines in augmentation and immunomodulation of host defenses against Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: in vitro effect of r-metHuG-CSF (Filgrastim).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

The role of G-CSF in adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Cytokines and fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

The colony-stimulating factors: use to prevent and treat neutropenia and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Immunotherapy for invasive fungal infections: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of l

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Haematopoietic growth factors in children with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Multiple fungal brain abscess in a child with acute myeloblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Successful treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Adjunctive immune therapy for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Clinical perspectives of granulocyte transfusions: efficacy to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

G-CSF mobilised granulocyte transfusions in 32 paediatric patients with neutropenic sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Return of granulocyte transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Cataracts in neutrophil donors stimulated with adrenal corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Immunotherapy for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Vaccines that facilitate antigen entry into dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Protective antifungal yeast killer toxin-like antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Cell biology. A fungal Achilles' heel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Fungal heat-shock proteins in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Genetically recombinant antibodies: new therapeutics against candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Human recombinant antibody to HSP90: a natural partner in combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Toward more effective antifungal therapy: the prospects of combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Promising immunotherapies with Th1-related cytokines against infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

Beneficial Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Fungicidal Activity of Polymorphonuclear Leukocytes from Patients with AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.129

21 January 2018

Identifiers

DOI

10.1586/14787210.5.1.129

1 reference

15 August 2017

1 reference